Miraxion: Completed Phase III enrollment

AMRN completed enrollment of 300 patients in the double-blind, placebo-controlled, U.S and Canadian Phase III TREND trial. The trial has an SPA from FDA. Miraxion has Orphan Drug designations in the U...